Microgynon 20 (Ethinylestradiol, Levonorgestrel)

Microgynon 20, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.

• Pregnancy prevention: provides reliable contraception by inhibiting ovulation and altering cervical mucus.
• Menstrual cycle regulation: helps achieve more predictable bleeding patterns and reduces dysmenorrhea.
• Hormonal balance for women of reproductive age: can lessen menstrual‑related symptoms such as acne and premenstrual mood changes.

• Microgynon 20 contains ethinylestradiol, a synthetic estrogen, and levonorgestrel, a progestogen. The estrogen component suppresses the pituitary release of follicle‑stimulating hormone, while the progestogen blocks the luteinizing hormone surge, together preventing follicular development and ovulation. Additionally, levonorgestrel thickens cervical mucus and induces endometrial changes that are unfavorable for implantation, providing multiple mechanisms of contraceptive action. These hormonal effects are sustained throughout each 21‑day cycle when the tablet is taken daily as directed.

Microgynon 20 may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset, often transient.
• Breast tenderness: swelling or discomfort in the breasts.
• Headache: occasional throbbing or tension‑type pain.
• Breakthrough bleeding: spotting or irregular bleeding between periods.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism, requiring immediate medical attention.
• Arterial thrombosis: stroke or myocardial infarction, especially in high‑risk individuals.
• Severe allergic reaction: rash, swelling, or anaphylaxis that may be life‑threatening.

Before prescribing Microgynon 20, clinicians should evaluate several safety considerations.

• Assess thrombotic risk: review personal and family history of clotting disorders.
• Screen for hypertension: measure blood pressure and control elevated readings prior to use.
• Avoid in smokers over 35: counsel patients to cease smoking to reduce cardiovascular risk.
• Evaluate liver function: contraindicated in active liver disease or severe hepatic impairment.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Microgynon 20 can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin): markedly reduce hormone levels and contraceptive efficacy.
• Rifampicin: accelerates metabolism of both hormones, increasing risk of unintended pregnancy.
• Certain antivirals (e.g., ritonavir): may affect steroid metabolism and compromise contraceptive reliability.

Moderate Interactions (Monitor Closely)

• Broad‑spectrum antibiotics (e.g., tetracycline, metronidazole): may slightly diminish contraceptive effect.
• St John’s wort: herbal inducer that can lower plasma concentrations of ethinylestradiol and levonorgestrel.
• Selective serotonin reuptake inhibitors: may increase the incidence of mood‑related side effects.